Articles tagged with Breast Cancer
Researchers identified PKC-delta as a critical regulator of cisplatin-mediated kidney toxicity, and inhibiting it protected the kidneys without blocking chemotherapy efficacy in mouse models. Additionally, studies divided breast cancers into subtypes to identify effective therapies for triple-negative breast cancer patients.
Researchers at Dana-Farber Cancer Institute have identified an overactive network of growth-spurring genes that drive stem-like breast cancer cells enriched in triple-negative breast tumors. The Jak2/Stat3 pathway was found to be elevated in these cells, and a drug specifically aimed at blocking this pathway halted tumor growth in mice.
A recent study by Oregon State University researchers found that breast cancer survivors used online forums to share their personal experiences and challenge scientific authority. The women's reactions were intensified by their online connection to others who shared similar experiences, leading to a shift in the balance of power betwee...
A protein activated by diabetes drugs may slow cancer spread in breast tumors, and removing it increases cancer risk. Women exposed to environmental pollutants or poor diets are more likely to develop aggressive breast cancers.
Researchers found that cancer cells induce oxidative stress in normal connective tissue to extract vital nutrients, accelerating aging and inflammation. This process can identify breast cancer patients at risk of metastasis and offers a potential therapeutic target via antioxidant and anti-inflammatory drugs.
A UNC laboratory study shows that Tacrolimus, a commonly used organ transplant rejection medication, inhibits breast cancer growth by over 70 percent in pre-clinical studies. The drug works by blocking new blood vessel growth to tumors, a therapeutic strategy to inhibit tumor growth.
A new study suggests that lipofilling is a safe procedure for women with breast cancer, with no significant difference in local recurrence rates between the treatment group and controls. However, longer follow-up and more research are needed to confirm these findings.
Researchers have discovered a link between a variant of the fat mass and obesity associated gene (FTO) and an increased incidence of breast cancer. The study, published in BMC Medical Genetics, found that people with this genetic variant have a 30% higher chance of developing breast cancer.
Scientists have discovered a protein involved in drug resistance in breast cancer, which could be targeted for new treatments. Blocking the production of this protein in human cells made them more responsive to anti-oestrogen drugs.
Research suggests that doctors should tailor treatment to specific qualities of second tumor, regardless of whether it's old or new. Studies found that 89% of recurring tumors differed in at least one characteristic compared to the original tumor.
Researchers at Thomas Jefferson University discovered a biomarker Stat5 in breast cancer that predicts patient response to anti-estrogen therapy tamoxifen. Women with active Stat5 have an increased likelihood of responding to the treatment, while those without it are at a higher risk of dying from breast cancer.
Researchers have discovered a new mechanism of action for Herceptin, revealing its ability to stimulate interferons and activate lymphocytes. Combining Herceptin with lymphocyte-stimulating therapies greatly increases efficacy in animals, paving the way for targeted therapies.
Researchers at VCU Massey Cancer Center have found a new biomarker related to the immune system that can predict breast cancer recurrence. The five-gene signature shows over 85% accuracy in predicting relapse-free survival.
Researchers discovered that breast cancer cells can thrive under starvation conditions by using fatty acids as an alternative energy source. The protein CPT1C plays a key role in this adaptation, and its expression is increased under conditions of metabolic stress.
Researchers discovered a new way breast cancer cells adapt to starvation conditions by turning to fatty acids for energy. This adaptation highlights the resilience of cancer cells and could lead to targeted therapies that block their ability to survive.
A recent study published in Breast Cancer Research found that coffee consumption is associated with a lower incidence of ER-negative breast cancer. The research, which adjusted for other lifestyle factors, suggests that moderate coffee consumption may offer protective effects against this type of breast cancer.
A new genomic test has shown promise as a predictor of chemotherapy response and survival benefit in women with invasive breast cancer. The test combines multiple signatures, including estrogen receptor status, endocrine therapy response, chemotherapy resistance and sensitivity, to predict treatment outcomes.
A new predictive test developed from gene expression microarrays identified patients with a high probability of survival following chemotherapy for breast cancer. The test had a positive predictive value of 56 percent and showed significant association between predicted sensitivity to treatment and improved distant relapse-free survival.
Researchers found that apigenin in parsley and celery can delay and reduce breast cancer tumor formation by blocking blood vessel growth. The study suggests incorporating these plant-based compounds into daily diets may help prevent breast cancer progression in women taking hormone replacement therapies.
Researchers found that estrogen-lowering drugs can shrink tumors and reduce mastectomy rates for patients with stage 2 or 3 breast cancer. Aromatase inhibitors, which block the production of estrogen, were shown to be effective in reducing tumor size and improving surgical outcomes.
Chronic diseases are a major concern in Brazil, driven by increasing prevalence of risk factors such as obesity, hypertension, and diabetes. The country has made significant progress in combating non-communicable diseases (NCDs), with age-standardised mortality rates declining by 1.8% per year since 1996.
French researchers have reported the strongest proof yet that circulating tumor cells found in patient blood are linked to poor outcomes. The study suggests using a threshold of 1 CTC for defining high-risk patients, supporting its use in non-metastatic breast cancer patients.
Researchers at UNC Chapel Hill School of Medicine isolated normal stem cells with aggressive breast cancer properties and identified a genetic intersection that contributes to metastasis. The study suggests a new target for treating triple negative breast cancer.
Researchers used Foerster resonance energy transfer (FRET) imaging to measure protein interactions on breast cancer cells, revealing a 'signature' representing functional molecular biology. This signature may help predict patient outcome in terms of likelihood of recurrence and response to treatment like lapatinib.
Researchers have identified sFRP1 as a molecular marker that correlates with chemotherapy sensitivity in triple-negative breast cancers. The study found that sFRP1 expression levels in individual tumors predict response to chemotherapy, and knocking down the gene in cell culture decreased sensitivity to certain chemotherapies.
Researchers found that celecoxib induced an anti-tumor response at the molecular level, affecting genes involved in cell proliferation, apoptosis, and extracellular matrix biology. The study suggests that celecoxib may be efficient as a cancer treatment for people with primary invasive breast cancer.
Two widely used multi-gene tests produce broadly similar results for high- and low-risk breast cancer patients, but differ for those at intermediate risk. The study's findings suggest that these tests can provide additional independent prognostic information to help clinicians make informed treatment decisions.
A new study finds that breast shields can significantly reduce skin entrance radiation dose to the breast by up to 38% without increasing overall radiation dose. This technique is considered the best method for protecting women from radiation exposure during chest CT examinations.
Two new studies show a significant drop in mammograms performed in women aged 40-49, leading to decreased benefits of early detection. Researchers found that cancers detected earlier through screening mammography presented at an earlier stage than those not screened, resulting in lower survival rates if guidelines are followed.
A new study found that annual mammograms are as effective as interval post-treatment mammograms in detecting breast cancer recurrences. The research suggests eliminating the interval mammogram would save healthcare costs without negatively impacting patient outcomes, decreasing unnecessary biopsies and stress.
A study found that Medicare reimbursement policy significantly affects the use of costly breast cancer therapy, including intensity-modulated radiation therapy (IMRT). The analysis showed a sharp increase in IMRT usage and costs between 2001 and 2005, with billing rates varying by region and treatment setting.
Scientists have developed a new imaging agent using tantalum oxide nanoparticles, which stays in the body long enough to image multiple organs. The material is inexpensive and has shown promising results in laboratory tests, potentially overcoming limitations of existing imaging agents.
A phase III clinical trial will recruit 4,000 women with low to intermediate Oncotype DX recurrence scores to determine whether a gene expression test can spare thousands of women from unnecessary chemotherapy. The RxPONDER trial aims to identify an optimal recurrence score cutpoint for these patients.
Research at the University at Buffalo found that early life air pollution exposure and motherhood may alter DNA, increasing premenopausal breast cancer risk. Decreased E-cadherin promoter methylation was associated with higher birth exposure, while increased p16 methylation linked to first child birth in higher-pollution areas.
Researchers will test a novel antibody against TGFβ to enhance radiation therapy's effectiveness in metastatic breast cancer patients. The goal is to induce an immune response against tumor sites outside the radiation field.
Two studies published in JAMA describe the first clinical applications of whole-genome sequencing in patients with cancer, enabling targeted therapies based on genetic mutations. The technology is becoming increasingly affordable, with costs expected to drop below $10,000 within five years.
A biophysicist is developing a drug that targets Interleukin-6 (IL-6) to combat breast and prostate cancer. By blocking the protein's signaling pathway, researchers aim to prevent cellular inflammation and tumor growth.
A study by UCLA researchers found that ACE inhibitors may increase the risk of breast cancer recurrence in women who have had early-stage breast cancer. In contrast, beta blockers appeared to have a protective effect, and when used together with ACE inhibitors, may help mitigate this risk.
Researchers at the University of Calgary developed a new digital tool using fractal dimension analysis to assess breast cancer tumours. The method provides an objective and reproducible measure of tissue abnormality and aggressiveness, promising more accurate risk assessment and therapeutic decisions.
Researchers found that healthy breast cells secrete interleukin 25 to actively kill nearby breast cancer cells without harming normal cells. This discovery suggests IL25 receptor signaling as a new therapeutic target for treating breast cancer.
The sentinel node procedure has evolved to limit surgical overtreatment, but isolated tumor cells and micrometastases have led to increased surgeries. Current studies examine the role of radiotherapy, pathologic protocols, and prognostic impact of these findings on breast cancer patients.
A clinical study suggests that a specific combination of nutritional ingredients, including indole-3 carbinol and vitamin D, may increase the mean urinary concentration of 2-OHE in pre- and post-menopausal women by 110% and 88%, respectively. The supplement was well-tolerated with no adverse side effects.
New research from the University of Oregon found that breast cancer awareness campaigns have reduced fluctuations in diagnoses, with most cases now linked to routine screenings. The study suggests that increased awareness and advocacy efforts have led to better screening rates among American women.
Researchers found that fish oil increases expression of genes related to cellular specialization, differentiation, and immune defenses against tumors. However, it also triggers counterproductive immune responses like inflammation and allergic reactions.
A recent study suggests that breast cancer patients experiencing persistent fatigue may have an imbalance in their autonomic nervous system, leading to accelerated aging. Researchers found that fatigued patients showed higher levels of stress hormones and lower parasympathetic activity compared to non-fatigued patients.
A study in the American Journal of Preventive Medicine found that US women were confused by recent mammography screening recommendations, with 30% more confused than helped. The majority of media coverage was unsupportive, and women aged 40-49 years were most likely to be confused.
An observational study found that women with poor physical health scores had a 27% increased risk of cancer recurrence or new breast cancer. Physical health also impacted survival, with a 65% greater risk of death among those with poorer health scores.
Breast cancer survivors who experience large weight gain (10% or more over pre-diagnosis weight) are 14% more likely to experience a cancer recurrence compared to women whose weight remains stable. Researchers found that moderate weight gain does not affect breast cancer outcomes.
A recent study published by the American Association for Cancer Research found that consuming soy food did not increase the risk of cancer recurrence or death among breast cancer survivors. In fact, women who consumed more soy isoflavones had a reduced risk of mortality and cancer recurrence compared to those with lower intake levels.
A recent study suggests that estrogen-only hormone therapy may decrease the risk of breast cancer in women who have had a hysterectomy. However, experts caution against long-term use due to unknown consequences and conflicting evidence from previous studies.
Breast cancer survivors who experience extreme weight gain have an increased risk of death and cancer recurrence. Moderate weight gain did not affect breast cancer outcomes, according to a study presented at the AACR 102nd Annual Meeting.
Researchers at the University of Pennsylvania School of Medicine have found a novel drug combination that successfully treats advanced cancer patients. The temsirolimus-hydroxychloroquine combination was shown to halt tumor growth in two-thirds of patients, including those with melanoma, colorectal, and head and neck cancers.
Researchers at Fox Chase Cancer Center have discovered a gene expression pattern in breast tissue that differs between post-menopausal women who had children and those who did not. This genomic signature may help scientists understand why pregnancy reduces breast cancer risk and develop chemopreventive strategies.
A longer-term follow-up of postmenopausal women who used estrogen therapy for 6 years found that the increased risk of stroke during treatment had dissipated, while the decreased risk of breast cancer persisted. The risk of hip fracture was not maintained during the postintervention phase.
Researchers found that vitamin D significantly reduced estrogen receptor-positive (ER+) breast cancer in both lean and obese mice, but had no effect on estrogen receptor-negative (ER-) cancer. Vitamin D also reversed insulin resistance in obese mice, while having no benefit in lean mice.
Researchers found that social isolation combined with a high-fat diet increases levels of a brain neurotransmitter called neuropeptide Y, promoting obesity, insulin resistance, and breast cancer risk in mice. The study's findings suggest a link between human social isolation and elevated cancer risk.
Researchers have developed a method to assess breast cancer risk using epithelial cells found in breast milk. The study showed that average RASSF1 methylation levels were higher in biopsied breasts compared to non-biopsied breasts, suggesting a potential correlation between epigenetic signals and breast cancer risk.
A new study suggests that the soy-based compound Natural S-equol does not increase the risk of estrogen-sensitive breast cancer. Supplements containing SE5-OH have reduced menopause symptoms in postmenopausal women, and the study's findings enhance our understanding of Natural S-equol's safety profile.
A new study confirms that genetic differences exist in breast tissue across racial groups, which may explain disparities in breast cancer morbidity and mortality. The research found varying levels of genes related to the DNA repair pathway, a known mechanism in cancer.
Researchers at Queen's University Belfast have developed a new drug that prevents tumor growth by cutting off their blood supply, showing promise for treating prostate and breast cancers. The treatment targets tumor angiogenesis using an entirely different pathway than existing therapies.